Aktienanalyse zu Bausch + Lomb Corp (BLCO)BLCOBausch + Lomb Corp

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

Bausch + Lomb Corp (BLCO) is a good buy right now, trading at $16.49, with a forward P/E ratio of 11.36, suggesting it is undervalued compared to its earnings potential. The recent insider buying has increased by 704.32%, indicating strong confidence from those within the company. However, the main risk is the negative net income, which was -71 million USD in Q1 2026, highlighting ongoing profitability challenges.